FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109304329> ?p ?o ?g. }

• W2109304329 endingPage "275" @default.
• W2109304329 startingPage "269" @default.
• W2109304329 abstract "Psoriasis is a chronic, genetically determined, immune-mediated, inflammatory skin disease affecting approximately 2% to 3% of the Caucasian population. Previously reported data demonstrated adalimumab to be an efficacious treatment of psoriatic arthritis and plaque-type psoriasis. Adalimumab is a fully human monoclonal antibody IgG1 against tumor necrosis factor alpha.To evaluate the efficacy and safety of adalimumab, in the treatment of psoriasis patients whose disease is refractory to treatment with other biologic agents.Thirty patients affected by plaque-type psoriasis with or without psoriatic arthritis, unresponsive to conventional and biologic systemic treatments were enrolled. Adalimumab was administered in monotherapy, at a dosage of 40 mg, subcutaneously, once a week.At week 12, 26 of 30 patients (87%) achieved Psoriasis Area and Severity Index (PASI) 75; at week 24, 25 of 30 patients (83%) achieved PASI 75. Concerning psoriatic arthritis, at week 24, the mean Health Assessment Questionnaire score improved from 0.99 to 0.2, Ritchie articular index from 10.15 to 2, and Pain Visual Assessment Score from 6.32 to 1.2. Furthermore, therapy with adalimumab considerably enhanced patients' quality of life as assessed by two measures (Dermatology Life Quality Index, Psoriasis Disability Index). Adalimumab was generally safe and well tolerated.This is not a randomized placebo-controlled study and is restricted to a small number of patients.In our experience, although preliminary, monotherapy with adalimumab 40 mg weekly proved to be an effective and safe treatment for the management of plaque-type psoriasis and psoriatic arthritis, with a rapid onset of action in patients whose disease had been refractory to both conventional and biologic agents." @default.
• W2109304329 created "2016-06-24" @default.
• W2109304329 creator A5004401304 @default.
• W2109304329 creator A5022739370 @default.
• W2109304329 creator A5036267976 @default.
• W2109304329 creator A5046567040 @default.
• W2109304329 creator A5053176930 @default.
• W2109304329 creator A5065367798 @default.
• W2109304329 creator A5075368922 @default.
• W2109304329 creator A5075659127 @default.
• W2109304329 date "2007-08-01" @default.
• W2109304329 modified "2023-09-26" @default.
• W2109304329 title "Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics" @default.
• W2109304329 cites W1985004174 @default.
• W2109304329 cites W1997299625 @default.
• W2109304329 cites W2008716526 @default.
• W2109304329 cites W2009542486 @default.
• W2109304329 cites W2012581664 @default.
• W2109304329 cites W2020776325 @default.
• W2109304329 cites W2030348118 @default.
• W2109304329 cites W2064564154 @default.
• W2109304329 cites W2066243006 @default.
• W2109304329 cites W2069070000 @default.
• W2109304329 cites W2089696290 @default.
• W2109304329 cites W2091442391 @default.
• W2109304329 cites W2096991001 @default.
• W2109304329 cites W2106686862 @default.
• W2109304329 cites W2133696182 @default.
• W2109304329 cites W2141008039 @default.
• W2109304329 cites W2155934675 @default.
• W2109304329 cites W2168698481 @default.
• W2109304329 cites W2172257129 @default.
• W2109304329 cites W4232214719 @default.
• W2109304329 cites W4233561050 @default.
• W2109304329 cites W4249483860 @default.
• W2109304329 doi "https://doi.org/10.1016/j.jaad.2006.12.003" @default.
• W2109304329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17574299" @default.
• W2109304329 hasPublicationYear "2007" @default.
• W2109304329 type Work @default.
• W2109304329 sameAs 2109304329 @default.
• W2109304329 citedByCount "118" @default.
• W2109304329 countsByYear W21093043292012 @default.
• W2109304329 countsByYear W21093043292013 @default.
• W2109304329 countsByYear W21093043292014 @default.
• W2109304329 countsByYear W21093043292015 @default.
• W2109304329 countsByYear W21093043292016 @default.
• W2109304329 countsByYear W21093043292017 @default.
• W2109304329 countsByYear W21093043292018 @default.
• W2109304329 countsByYear W21093043292019 @default.
• W2109304329 countsByYear W21093043292020 @default.
• W2109304329 countsByYear W21093043292021 @default.
• W2109304329 countsByYear W21093043292022 @default.
• W2109304329 crossrefType "journal-article" @default.
• W2109304329 hasAuthorship W2109304329A5004401304 @default.
• W2109304329 hasAuthorship W2109304329A5022739370 @default.
• W2109304329 hasAuthorship W2109304329A5036267976 @default.
• W2109304329 hasAuthorship W2109304329A5046567040 @default.
• W2109304329 hasAuthorship W2109304329A5053176930 @default.
• W2109304329 hasAuthorship W2109304329A5065367798 @default.
• W2109304329 hasAuthorship W2109304329A5075368922 @default.
• W2109304329 hasAuthorship W2109304329A5075659127 @default.
• W2109304329 hasConcept C126322002 @default.
• W2109304329 hasConcept C142724271 @default.
• W2109304329 hasConcept C16005928 @default.
• W2109304329 hasConcept C17991360 @default.
• W2109304329 hasConcept C204787440 @default.
• W2109304329 hasConcept C27081682 @default.
• W2109304329 hasConcept C2776173921 @default.
• W2109304329 hasConcept C2776260265 @default.
• W2109304329 hasConcept C2777011040 @default.
• W2109304329 hasConcept C2777077863 @default.
• W2109304329 hasConcept C2780132546 @default.
• W2109304329 hasConcept C2780564577 @default.
• W2109304329 hasConcept C71924100 @default.
• W2109304329 hasConceptScore W2109304329C126322002 @default.
• W2109304329 hasConceptScore W2109304329C142724271 @default.
• W2109304329 hasConceptScore W2109304329C16005928 @default.
• W2109304329 hasConceptScore W2109304329C17991360 @default.
• W2109304329 hasConceptScore W2109304329C204787440 @default.
• W2109304329 hasConceptScore W2109304329C27081682 @default.
• W2109304329 hasConceptScore W2109304329C2776173921 @default.
• W2109304329 hasConceptScore W2109304329C2776260265 @default.
• W2109304329 hasConceptScore W2109304329C2777011040 @default.
• W2109304329 hasConceptScore W2109304329C2777077863 @default.
• W2109304329 hasConceptScore W2109304329C2780132546 @default.
• W2109304329 hasConceptScore W2109304329C2780564577 @default.
• W2109304329 hasConceptScore W2109304329C71924100 @default.
• W2109304329 hasIssue "2" @default.
• W2109304329 hasLocation W21093043291 @default.
• W2109304329 hasLocation W21093043292 @default.
• W2109304329 hasOpenAccess W2109304329 @default.
• W2109304329 hasPrimaryLocation W21093043291 @default.
• W2109304329 hasRelatedWork W107859310 @default.
• W2109304329 hasRelatedWork W1589811210 @default.
• W2109304329 hasRelatedWork W2032220015 @default.
• W2109304329 hasRelatedWork W2109304329 @default.
• W2109304329 hasRelatedWork W2145093133 @default.
• W2109304329 hasRelatedWork W2168297071 @default.

• next